The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: Two Pivotal, Placebo Controlled, Double-Blind, Parallel-Group, Adaptive Trials

Trial Profile

The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: Two Pivotal, Placebo Controlled, Double-Blind, Parallel-Group, Adaptive Trials

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Rexmyelocel T (Primary)
  • Indications Peripheral ischaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Rexgenero
  • Most Recent Events

    • 14 Jan 2017 Planned number of patients changed from 141 to 60.
    • 05 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top